Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
GTN may leads to lower NON ‐ Healing of fissure (persistence or recurrence) compared with placebo (low certainty).